Please use this identifier to cite or link to this item: http://docs.prosentient.com.au/prosentientjspui/handle/1/10261
Title: Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children.
Authors: Jayasinghe, Sanjay
Chiu, Clayton
Menzies, Rob
Lehmann, Deborah
Cook, Heather
Giele, Carolien
Krause, Vicki
McIntyre, Peter
Affiliation: National Centre for Immunisation Research and Surveillance for Vaccine Preventable Diseases, Westmead, Australia; Discipline of Paediatrics and Child Health, University of Sydney, Sydney, Australia. Electronic address: sanjay.jayasinghe@health.nsw.gov.au..
National Centre for Immunisation Research and Surveillance for Vaccine Preventable Diseases, Westmead, Australia; Discipline of Paediatrics and Child Health, University of Sydney, Sydney, Australia..
National Centre for Immunisation Research and Surveillance for Vaccine Preventable Diseases, Westmead, Australia; School of Public Health and Community Medicine, University of New South Wales, Australia..
Telethon Kids Institute, the University of Western Australia, Perth, Western Australia, Australia..
Centre for Disease Control, Department of Health, Northern Territory, Australia..
Communicable Disease Control Directorate, Department of Health, Western Australia, Australia..
Centre for Disease Control, Department of Health, Northern Territory, Australia..
National Centre for Immunisation Research and Surveillance for Vaccine Preventable Diseases, Westmead, Australia; Discipline of Paediatrics and Child Health, University of Sydney, Sydney, Australia; School of Public Health, University of Sydney, Sydney, Australia..
Issue Date: 27-Nov-2015
Citation: Vaccine 2015-11-27; 33(48): 6666-74
Abstract: High incidence and serotype diversity of invasive pneumococcal disease (IPD) in Indigenous children in remote Australia led to rapid introduction of 7-valent conjugate pneumococcal vaccine (7vPCV) at 2, 4 and 6 months in 2001, followed by 23-valent polysaccharide pneumococcal vaccine (23vPPV) in the second year of life. All other Australian children were offered 3 doses of 7vPCV without a booster from 2005. This study evaluated the impact of the unique pneumococcal vaccine schedule of 7vPCV followed by the 23vPPV booster among Indigenous Australian children. Changes in IPD incidence derived from population-based passive laboratory surveillance in Indigenous children <5 years eligible for 23vPPV were compared to non-Indigenous eligible for 7vPCV only from the pre-vaccine introduction period (Indigenous 1994-2000; non-Indigenous 2002-2004) to the post-vaccine period (2008-2010 in both groups) using incidence rate ratios (IRRs) stratified by age into serotype groupings of vaccine (7v and 13vPCV and 23vPPV) and non-vaccine types. Vaccine coverage was assessed from the Australian Childhood Immunisation Register. At baseline, total IPD incidence per 100,000 was 216 (n=230) in Indigenous versus 55 (n=1993) in non-Indigenous children. In 2008-2010, IRRs for 7vPCV type IPD were 0.03 in both groups, but for 23v-non7v type IPD 1.2 (95% CI 0.8-1.8) in Indigenous versus 3.1 (95% CI 2.5-3.7) in non-Indigenous, difference driven primarily by serotype 19A IPD (IRR 0.6 in Indigenous versus 4.3 in non-Indigenous). For non-7vPCV type IPD overall, IRR was significantly higher in those age-eligible for 23vPPV booster compared to those younger, but in both age groups was lower than for non-Indigenous children. These ecologic data suggest a possible "serotype replacement sparing" effect of 23vPPV following 7vPCV priming, especially for serotype 19A with supportive evidence from other immunogenicity and carriage studies. Applicability post 10vPCV or 13v PCV priming in similar settings would depend on local serotype distribution of IPD.
URI: http://docs.prosentient.com.au/prosentientjspui/handle/1/10261
DOI: 10.1016/j.vaccine.2015.10.089
Type: Journal Article
Observational Study
Subjects: Indigenous
Invasive pneumococcal disease epidemiology
Pneumococcal conjugate vaccine
Pneumococcal disease
Pneumococcal polysaccharide vaccine
Australia
Child, Preschool
Female
Heptavalent Pneumococcal Conjugate Vaccine
Humans
Incidence
Infant
Male
Pneumococcal Infections
Pneumococcal Vaccines
Population Groups
Serogroup
Streptococcus pneumoniae
Immunization Schedule
Appears in Collections:NT Health digital library

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.